| Year |
Citation |
Score |
| 2023 |
Galvan GC, Friedrich NA, Das S, Daniels JP, Pollan S, Dambal S, Suzuki R, Sanders SE, You S, Tanaka H, Lee YJ, Yuan W, de Bono JS, Vasilevskaya I, Knudsen KE, et al. 27-hydroxycholesterol and DNA damage repair: implication in prostate cancer. Frontiers in Oncology. 13: 1251297. PMID 38188290 DOI: 10.3389/fonc.2023.1251297 |
0.398 |
|
| 2023 |
Zhao JL, Antonarakis ES, Cheng HH, George DJ, Aggarwal R, Riedel E, Sumiyoshi T, Schonhoft JD, Anderson A, Mao N, Haywood S, Decker B, Curley T, Abida W, Feng FY, ... Knudsen K, et al. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). British Journal of Cancer. PMID 37980367 DOI: 10.1038/s41416-023-02487-5 |
0.409 |
|
| 2023 |
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song WM, Fujiwara N, Li P, Mendizabal I, Petrylak DP, Kelly WK, Reddy EP, Wang L, Schiewer MJ, ... ... Knudsen KE, et al. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discovery. PMID 37676710 DOI: 10.1158/2159-8290.CD-23-0306 |
0.413 |
|
| 2023 |
Slovin SF, Knudsen K, Halabi S, de Leeuw R, Shafi A, Kang P, Wolf S, Luo B, Gopalan A, Curley T, Fleming M, Molina A, Fernandez C, Kelly K. Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202639. PMID 37582240 DOI: 10.1200/JCO.22.02639 |
0.376 |
|
| 2023 |
Gordon N, Gallagher PT, Neupane NP, Mandigo AC, McCann JK, Dylgjeri E, Vasilevskaya I, McNair C, Paller CJ, Kelly WK, Knudsen KE, Shafi AA, Schiewer MJ. PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. Biorxiv : the Preprint Server For Biology. PMID 36993449 DOI: 10.1101/2023.03.23.533944 |
0.451 |
|
| 2022 |
Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D, Szmulewitz R, Sartor O, Knudsen K, Yang ES, Kelly WK. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36321991 DOI: 10.1158/1078-0432.CCR-22-2526 |
0.413 |
|
| 2021 |
Mandigo AC, Shafi AA, McCann JJ, Yuan W, Laufer TS, Bogdan D, Gallagher L, Dylgjeri E, Semenova G, Vasilevskaya IA, Schiewer MJ, McNair C, de Bono JS, Knudsen KE. Novel oncogenic transcription factor cooperation in RB-deficient cancer. Cancer Research. PMID 34625422 DOI: 10.1158/0008-5472.CAN-21-1159 |
0.507 |
|
| 2021 |
Mandigo AC, Tomlins SA, Kelly WK, Knudsen KE. Relevance of pRB Loss in Human Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34407969 DOI: 10.1158/1078-0432.CCR-21-1565 |
0.336 |
|
| 2021 |
Schiewer MJ, Knudsen KE. Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. The Urologic Clinics of North America. 48: 339-347. PMID 34210489 DOI: 10.1016/j.ucl.2021.04.004 |
0.506 |
|
| 2021 |
Nakken S, Lilleby W, Switlyk MD, Knudsen KE, Lilleby O, Zhao S, Kaveh F, Ekstrøm PO, Urbanucci A, Hovig E. The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology. Journal of Personalized Medicine. 11. PMID 33922147 DOI: 10.3390/jpm11050330 |
0.438 |
|
| 2021 |
Mandigo AC, Yuan W, Xu K, Gallagher P, Pang A, Guan YF, Shafi AA, Thangavel C, Sheehan B, Bogdan D, Paschalis A, McCann JJ, Laufer TS, Gordon N, Vasilevskaya IA, ... ... Knudsen KE, et al. RB/E2F1 as a master regulator of cancer cell metabolism in advanced disease. Cancer Discovery. PMID 33879449 DOI: 10.1158/2159-8290.CD-20-1114 |
0.317 |
|
| 2021 |
Palmbos PL, Daignault-Newton S, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora VK, Antonarakis ES, Siddiqui J, Jacobson J, Davenport MS, Robinson DR, Chinnaiyan AM, Knudsen KE, et al. A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33727260 DOI: 10.1158/1078-0432.CCR-21-0024 |
0.476 |
|
| 2021 |
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate cancer. Nature Reviews. Disease Primers. 7: 9. PMID 33542230 DOI: 10.1038/s41572-020-00243-0 |
0.468 |
|
| 2021 |
Quaglia F, Krishn SR, Wang Y, Goodrich DW, McCue P, Kossenkov AV, Mandigo AC, Knudsen KE, Weinreb PH, Corey E, Kelly WK, Languino LR. Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression. Plos One. 16: e0244985. PMID 33481853 DOI: 10.1371/journal.pone.0244985 |
0.47 |
|
| 2021 |
Shafi AA, McNair CM, McCann JJ, Alshalalfa M, Shostak A, Severson TM, Zhu Y, Bergman A, Gordon N, Mandigo AC, Chand SN, Gallagher P, Dylgjeri E, Laufer TS, Vasilevskaya IA, ... ... Knudsen KE, et al. The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. Nature Communications. 12: 401. PMID 33452241 DOI: 10.1038/s41467-020-20513-5 |
0.308 |
|
| 2021 |
Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, Pal A, Figueiredo I, Riisnaes R, Gurel B, Rekowski J, Bogdan D, West W, Young B, Raja M, ... ... Knudsen KE, et al. Targeting p300/CBP axis in lethal prostate cancer. Cancer Discovery. PMID 33431496 DOI: 10.1158/2159-8290.CD-20-0751 |
0.522 |
|
| 2020 |
Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, ... ... Knudsen KE, et al. The DNA methylation landscape of advanced prostate cancer. Nature Genetics. PMID 32661416 DOI: 10.1038/S41588-020-0648-8 |
0.46 |
|
| 2020 |
Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000046. PMID 32516092 DOI: 10.1200/Jco.20.00046 |
0.493 |
|
| 2020 |
Mardis ER, Ribas A, Hait WN, Jaffee EM, Foti M, Abate-Shen C, Albini A, Bernards R, Cruz-Correa MR, Flaherty KT, Greenberg PD, June CH, Knudsen KE, Liu ET, Mills GB, et al. AACR calls on congress to take immediate action against COVID-19 and protect patients with cancer during the pandemic Cancer Discovery. 10: 771-774. PMID 32295764 DOI: 10.1158/2159-8290.Cd-20-0449 |
0.341 |
|
| 2020 |
Woo J, Santasusagna S, Banks J, Pastor-Lopez S, Yadav K, Carceles-Cordon M, Dominguez-Andres A, Den RB, Languino L, Pippa R, Lallas CD, Luyao G, Kelly WK, Knudsen KE, Rodriguez-Bravo V, et al. Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32250729 DOI: 10.1097/Ju.0000000000001066 |
0.513 |
|
| 2020 |
Carceles-Cordon M, Kelly WK, Gomella L, Knudsen KE, Rodriguez-Bravo V, Domingo-Domenech J. Cellular rewiring in lethal prostate cancer: the architect of drug resistance. Nature Reviews. Urology. PMID 32203305 DOI: 10.1038/S41585-020-0298-8 |
0.438 |
|
| 2020 |
Mandigo AC, Knudsen KE. Double Trouble: Concomitant RB1 and BRCA2 depletion evokes aggressive phenotypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32019859 DOI: 10.1158/1078-0432.Ccr-19-4033 |
0.504 |
|
| 2020 |
Jensen RA, Knudsen KE, Platanias LC. Disclose and Manage Conflicts of Interest at Cancer Centers. Jama Internal Medicine. 180: 161. PMID 31904783 DOI: 10.1001/Jamainternmed.2019.5542 |
0.316 |
|
| 2020 |
Slovin SF, Knudsen KE, Halabi S, Fleming MT, Molina AM, Wolf SP, de Leeuw R, Fernandez C, Kang P, Southwell T, Jones CL, Fernandez E, Kelly WK. Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 84-84. DOI: 10.1200/Jco.2020.38.6_Suppl.84 |
0.514 |
|
| 2020 |
Vasilevskaya I, McCann J, McNair C, Neupane NP, Gallagher P, Knudsen KE. Significance of distinct specifically enriched missense TP53 mutations in prostate cancer. Journal of Clinical Oncology. 38: 377-377. DOI: 10.1200/Jco.2020.38.6_Suppl.377 |
0.424 |
|
| 2020 |
Mandigo AC, McNair C, Ku K, Pang A, Guan YF, Holst J, Brown M, Kelly WK, Knudsen KE. Molecular underpinnings of RB status as a biomarker of poor outcome in advanced prostate cancer. Journal of Clinical Oncology. 38: 189-189. DOI: 10.1200/Jco.2020.38.6_Suppl.189 |
0.555 |
|
| 2020 |
McNair C, Knudsen KE. Improving data accessibility: New strategies towards implementation of a genomic data portal. Journal of Clinical Oncology. 38: 159-159. DOI: 10.1200/Jco.2020.38.6_Suppl.159 |
0.336 |
|
| 2020 |
Palmbos PL, Tomlins SA, Daignault S, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora V, Antonarakis ES, Siddiqui J, Robinson D, Knudsen KE, Chinnaiyan A, Hussain MHA. Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 38: 5573-5573. DOI: 10.1200/Jco.2020.38.15_Suppl.5573 |
0.462 |
|
| 2019 |
McCann JJ, Vasilevskaya IA, Poudel Neupane N, Shafi AA, McNair C, Dylgjeri E, Mandigo AC, Schiewer MJ, Schrecengost RS, Gallagher P, Stanek TJ, McMahon SB, Berman-Booty LD, Ostrander WF, Knudsen KE. USP22 functions as an oncogenic driver in prostate cancer by regulating cell proliferation and DNA repair. Cancer Research. PMID 31740444 DOI: 10.1158/0008-5472.Can-19-1033 |
0.561 |
|
| 2019 |
Cosper PF, McNair C, González I, Wong N, Knudsen KE, Chen JJ, Markovina S, Schwarz JK, Grigsby PW, Wang X. Decreased Local Immune Response and Retained HPV Gene Expression during Chemoradiotherapy are Associated with Treatment Resistance and Death from Cervical Cancer. International Journal of Cancer. PMID 31732968 DOI: 10.1002/Ijc.32793 |
0.325 |
|
| 2019 |
Marascio J, Spratt DE, Zhang J, Trabulsi EJ, Le T, Sedzorme WS, Beeler WH, Davicioni E, Dabbas B, Lin DW, Gore JL, Bloom M, Mann M, Mark JR, Calvaresi A, ... ... Knudsen KE, et al. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer and Prostatic Diseases. PMID 31719663 DOI: 10.1038/S41391-019-0185-7 |
0.436 |
|
| 2019 |
Knudsen KE. The AR-DNA repair axis: insights into prostate cancer aggressiveness. The Canadian Journal of Urology. 26: 22-23. PMID 31629421 |
0.453 |
|
| 2019 |
Gomella LG, Knudsen KE, Giri VN. Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'. The Canadian Journal of Urology. 26: 1-4. PMID 31629412 |
0.427 |
|
| 2019 |
Yoshida A, Bu Y, Qie S, Wrangle J, Camp ER, Hazard ES, Hardiman G, de Leeuw R, Knudsen KE, Diehl JA. SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Science Advances. 5: eaax6352. PMID 31555743 DOI: 10.1126/Sciadv.Aax6352 |
0.345 |
|
| 2019 |
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, ... ... Knudsen KE, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31363002 DOI: 10.1158/1078-0432.Ccr-19-1423 |
0.575 |
|
| 2019 |
Shafi AA, Knudsen KE. Cancer and the Circadian Clock. Cancer Research. PMID 31300477 DOI: 10.1158/0008-5472.Can-19-0566 |
0.408 |
|
| 2019 |
Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, ... ... Knudsen KE, et al. Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31266833 DOI: 10.1158/1078-0432.Ccr-18-2207 |
0.432 |
|
| 2019 |
Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, ... ... Knudsen KE, et al. DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31266829 DOI: 10.1158/1078-0432.Ccr-18-2387 |
0.546 |
|
| 2019 |
Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY. Novel RB1-loss transcriptomic signature is associated with poor clinical outcomes across cancer types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31010837 DOI: 10.1158/1078-0432.Ccr-19-0404 |
0.352 |
|
| 2019 |
Knudsen KE, Feng FY. Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset. European Urology. PMID 30885533 DOI: 10.1016/J.Eururo.2019.03.005 |
0.478 |
|
| 2019 |
Gordon N, Schiewer MJ, Gallagher P, Mandigo AC, Dylgjeri E, McNair C, De Leeuw R, Jones JK, Neupane NP, Shafi AA, Brand L, Kelly WK, Knudsen KE. Synergistic effects of the PARP inhibitor olaparib and pharmacological ascorbate in castration-resistant prostate cancer. Journal of Clinical Oncology. 37: 326-326. DOI: 10.1200/Jco.2019.37.7_Suppl.326 |
0.474 |
|
| 2019 |
Schiewer MJ, Mandigo AC, Gordon N, McNair C, Lallas CD, Trabulsi EJ, Leiby B, Knudsen KE. PARP-1 regulation of DNA repair factor availability. Journal of Clinical Oncology. 37: 269-269. DOI: 10.1200/Jco.2019.37.7_Suppl.269 |
0.406 |
|
| 2019 |
McCann JJ, Vasilevskaya I, PoudelNeupane N, Dean J, Mandigo A, Leeuw RD, McNair C, Schiewer M, Knudsen K. Abstract 4511: Prostate cancer-specific enrichment ofTP53missense mutations elicits differential, context-dependent biochemical and biologic outcomes Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4511 |
0.494 |
|
| 2019 |
Markt SC, Ebot E, Cheng I, Wilkens L, Shafi A, Knudsen K, Penney K, Mucci L, Gerke T. Abstract 1574: Circadian clock gene expression and lethal prostate cancer outcomes Epidemiology. DOI: 10.1158/1538-7445.Sabcs18-1574 |
0.497 |
|
| 2019 |
Mandigo AC, McNair C, Schiewer MJ, Knudsen KE. Abstract 5217: RB loss reprograms AR and E2F1 signaling in models of prostate cancer progression Cancer Research. 79: 5217-5217. DOI: 10.1158/1538-7445.Am2019-5217 |
0.614 |
|
| 2019 |
Dylgjeri E, Goodwin J, Shafi A, Kothari V, Zadra G, Seifert E, Feng F, Knudsen K. Abstract 1851: Novel roles of DNA-PK in metabolic regulation in prostate cancer Cancer Research. 79: 1851-1851. DOI: 10.1158/1538-7445.Am2019-1851 |
0.437 |
|
| 2018 |
Kelly WK, Knudsen KE. COUNTERPOINT-Prostate Cancer Genomic Analysis: Routine or Research Only? Oncology (Williston Park, N.Y.). 32. PMID 30632133 |
0.383 |
|
| 2018 |
Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, ... Knudsen KE, et al. Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. European Urology Oncology. 1: 325-337. PMID 30467556 DOI: 10.1016/J.Euo.2018.04.019 |
0.491 |
|
| 2018 |
Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, ... ... Knudsen KE, et al. PARP-1 regulates DNA repair factor availability. Embo Molecular Medicine. PMID 30467127 DOI: 10.15252/Emmm.201708816 |
0.385 |
|
| 2018 |
Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. The Prostate. PMID 30450585 DOI: 10.1002/Pros.23739 |
0.416 |
|
| 2018 |
Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, ... ... Knudsen KE, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 175: 889. PMID 30340047 DOI: 10.1016/J.Cell.2018.10.019 |
0.489 |
|
| 2018 |
Zhang AY, Chiam K, Haupt Y, Fox S, Birch S, Tilley W, Butler LM, Knudsen K, Comstock C, Rasiah K, Grogan J, Mahon KL, Bianco-Miotto T, Ricciardelli C, Bohm M, et al. An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy. International Journal of Cancer. PMID 30288742 DOI: 10.1002/Ijc.31906 |
0.734 |
|
| 2018 |
Nava Rodrigues D, Casiraghi N, Romanel A, Crespo M, Miranda S, Rescigno P, Figueiredo I, Riisnaes R, Carreira S, Sumanasuriya S, Gasperini P, Sharp A, Mateo J, Mackay A, McNair C, ... ... Knudsen KE, et al. RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30257982 DOI: 10.1158/1078-0432.Ccr-18-2068 |
0.446 |
|
| 2018 |
Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, Knudsen KE, Rui H, Butt T, Diehl JA, McMahon SB. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 30224477 DOI: 10.1073/Pnas.1807704115 |
0.5 |
|
| 2018 |
Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, Robinson JL, Schiewer MJ, Ma S, Kapur P, Sutherland PD, Hoffmann CE, Roehrborn CG, Gomella LG, Carroll JS, ... ... Knudsen KE, et al. A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology. PMID 30117261 DOI: 10.1002/1878-0261.12354 |
0.435 |
|
| 2018 |
Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, ... ... Knudsen KE, et al. Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. Cell. PMID 30100187 DOI: 10.1016/J.Cell.2018.07.015 |
0.547 |
|
| 2018 |
Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, ... ... Knudsen KE, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. PMID 30033370 DOI: 10.1016/J.Cell.2018.06.039 |
0.538 |
|
| 2018 |
de Leeuw R, McNair C, Schiewer MJ, Neupane NP, Brand LJ, Augello MA, Li Z, Cheng LC, Yoshida A, Courtney SM, Hazard S, Hardiman G, Hussain M, Diehl JA, Drake JM, ... ... Knudsen KE, et al. MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29739788 DOI: 10.1158/1078-0432.Ccr-18-0410 |
0.42 |
|
| 2018 |
Thangavel C, Perepelyuk M, Boopathi E, Liu Y, Polischak S, Deshpande DA, Rafiq K, Dicker AP, Knudsen KE, Shoyele SA, Den RB. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. Molecular Pharmaceutics. PMID 29616555 DOI: 10.1021/Acs.Molpharmaceut.7B01024 |
0.52 |
|
| 2018 |
Schiewer MJ, Knudsen KE. DNA Damage Response in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine. PMID 29530944 DOI: 10.1101/Cshperspect.A030486 |
0.48 |
|
| 2018 |
Thangavel C, Boopathi E, Liu Y, McNair C, Haber A, Perepelyuk M, Bhardwaj A, Addya S, Ertel A, Shoyele S, Birbe R, Salvino JM, Dicker AP, Knudsen KE, Den RB. Therapeutic Challenge With a CDK 4/6 Inhibitor Induces an RB-dependent SMAC Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29311118 DOI: 10.1158/1078-0432.Ccr-17-2074 |
0.408 |
|
| 2018 |
Godwin JL, Hoffman-Censits JH, Den RB, Knudsen KE, Schiewer MJ, Leiby BE, Southwell T, Hubert C, Patnaik A, Sonpavde G, Sartor AO, Yang ES, Kelly WK. c15-162: Phase IB trial of radium 223 and niraparib in patients with castrate resistant prostate cancer (NiraRad). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps385 |
0.523 |
|
| 2018 |
Kelly WK, Godwin JL, Hoffman-Censits JH, Knudsen KE, Leeuw RD, Leiby BE, Southwell T, Hubert C, Smith DC, Chatta GS, Aghalar J, Scher HI, Bose R, Autio KA, Abida W, et al. c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps384 |
0.527 |
|
| 2018 |
Zhang AY, Chiam K, Haupt Y, Fox SB, Birch S, Tilley W, Butler L, Knudsen KE, Cornstock C, Rasiah K, Grogan J, Mahon KL, Bianco-Miotto T, Bohm M, Henshall SM, et al. An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Journal of Clinical Oncology. 36: 54-54. DOI: 10.1200/Jco.2018.36.6_Suppl.54 |
0.417 |
|
| 2018 |
De Leeuw R, McNair C, Schiewer MJ, Neupane NP, Augello M, Li Z, Cheng L, Yoshida A, Diehl A, Hazard S, Courtney S, Hardiman G, Hussain M, Drake J, Kelly WK, ... Knudsen KE, et al. Effect of bypass kinase pathways on acquired CDK4/6 inhibitor resistance. Journal of Clinical Oncology. 36: 379-379. DOI: 10.1200/Jco.2018.36.6_Suppl.379 |
0.385 |
|
| 2018 |
Palmbos PL, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora V, Antonarakis ES, Siddiqui J, Daignault S, Knudsen KE, Feng FY, Hussain M. Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 36: 251-251. DOI: 10.1200/Jco.2018.36.6_Suppl.251 |
0.44 |
|
| 2018 |
Rathkopf DE, Autio KA, Antonarakis ES, Cheng HH, Arauz G, Slack A, Hullings M, Scher HI, Feng FY, Knudsen KE. c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study. Journal of Clinical Oncology. 36: 5045-5045. DOI: 10.1200/Jco.2018.36.15_Suppl.5045 |
0.569 |
|
| 2018 |
Knudsen KE. Abstract IA24: Targeting DNA repair dysfunction in advanced prostate cancer Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Tcm17-Ia24 |
0.576 |
|
| 2018 |
McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Laere BD, Dirix L, Visakorpi T, Li F, Feng FY, Bono Jd, Demichelis F, ... ... Knudsen KE, et al. Abstract IA03: Differential impact of RB pathway status on E2F1 reprogramming and disease progression in human prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-Ia03 |
0.579 |
|
| 2018 |
McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, Laere BD, Dirix L, Visakorpi T, Li F, Feng FY, Bono Jd, ... ... Knudsen KE, et al. Abstract B040: Differential impact of RB status on E2F1 reprogramming in human cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B040 |
0.482 |
|
| 2018 |
Butt S, Stanek TJ, Gennaro VJ, McNair C, Pauley KL, Knudsen K, McMahon SB. Abstract LB-A29: Divergent mechanisms of transcriptional regulation by SAGA member and epigenetic modifier USP22 Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A29 |
0.431 |
|
| 2017 |
Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, ... ... Knudsen KE, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017757310. PMID 29261439 DOI: 10.1200/Jco.2017.75.7310 |
0.439 |
|
| 2017 |
Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, et al. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017741173. PMID 29236593 DOI: 10.1200/Jco.2017.74.1173 |
0.376 |
|
| 2017 |
McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, ... ... Knudsen KE, et al. Differential impact of RB status on E2F1 reprogramming in human cancer. The Journal of Clinical Investigation. PMID 29202480 DOI: 10.1172/Jci93566 |
0.495 |
|
| 2017 |
Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. Response and resistance to paradox breaking BRAF inhibitor in melanomas in vivo and ex vivo. Molecular Cancer Therapeutics. PMID 29133617 DOI: 10.1158/1535-7163.Mct-17-0705 |
0.341 |
|
| 2017 |
Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, et al. Post-transcriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors. Cancer Research. PMID 28687616 DOI: 10.1158/0008-5472.Can-16-2704 |
0.395 |
|
| 2017 |
Paolillo C, Mu Z, Rossi G, Schiewer MJ, Nguyen T, Austin L, Capoluongo E, Knudsen KE, Cristofanilli M, Fortina P. Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28679775 DOI: 10.1158/1078-0432.Ccr-17-1173 |
0.34 |
|
| 2017 |
Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, ... ... Knudsen KE, et al. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports. 19: 2045-2059. PMID 28591577 DOI: 10.1016/J.Celrep.2017.05.049 |
0.576 |
|
| 2017 |
Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. PARP Inhibitors in Prostate Cancer. Current Treatment Options in Oncology. 18: 37. PMID 28540598 DOI: 10.1007/S11864-017-0480-2 |
0.501 |
|
| 2017 |
Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard CC, ... ... Knudsen KE, et al. Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discovery. PMID 28450426 DOI: 10.1158/2159-8290.Cd-17-0146 |
0.476 |
|
| 2017 |
Schiewer MJ, Knudsen KE. Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. Cancer Cell. 31: 471-473. PMID 28399406 DOI: 10.1016/J.Ccell.2017.03.012 |
0.311 |
|
| 2017 |
Thomas JD, Longen CG, Oyer HM, Chen N, Maher CM, Salvino JM, Kania B, Anderson KN, Ostrander WF, Knudsen KE, Kim FJ. Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. Cancer Research. PMID 28235766 DOI: 10.1158/0008-5472.Can-16-1055 |
0.597 |
|
| 2017 |
Brooks N, Pegg N, Worthington J, Young B, Prosser A, Lane J, Taddei D, Schiewer MJ, Gordon N, Knudsen KE. A novel small molecule inhibitor of p300/CBP for the treatment of castration-resistant prostate cancer: Preclinical evaluation. Journal of Clinical Oncology. 35: 168-168. DOI: 10.1200/Jco.2017.35.6_Suppl.168 |
0.509 |
|
| 2017 |
Palmbos PL, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora V, Antonarakis ES, Siddiqui J, Daignault S, Knudsen KE, Feng FY, Hussain M. Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 35: 151-151. DOI: 10.1200/Jco.2017.35.6_Suppl.151 |
0.525 |
|
| 2017 |
Slovin SF, Knudsen KE, Halabi S, Carbone E, Fernandez C, Chen Y, Autio KA, Rathkopf DE, Kampel LJ, Morris MJ, Arauz G, Graf RP, Kelvin J, Dittamore RV, De Leeuw R, et al. Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy. Journal of Clinical Oncology. 35: 5034-5034. DOI: 10.1200/Jco.2017.35.15_Suppl.5034 |
0.456 |
|
| 2017 |
Hussain M, Daignault S, Twardowski P, Albany C, Stein MN, Kunju LP, Robinson DR, Cooney KA, Montgomery RB, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, ... ... Knudsen KE, et al. Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data. Journal of Clinical Oncology. 35: 5001-5001. DOI: 10.1200/Jco.2017.35.15_Suppl.5001 |
0.355 |
|
| 2017 |
Pegg N, Brooks N, Worthington J, Young B, Prosser A, Lane J, Taddei D, Brown R, Harbottle G, Shannon J, Paoletta S, Knudsen KE. Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer. Journal of Clinical Oncology. 35: 11590-11590. DOI: 10.1200/Jco.2017.35.15_Suppl.11590 |
0.536 |
|
| 2017 |
Knudsen KE. Abstract IA26: Dual functions of PARP1 in prostate cancer: mechanisms and implications for therapeutic intervention Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-Ia26 |
0.574 |
|
| 2017 |
Butler LR, Ragland RL, Breslin HJ, George E, Gill T, Scheiwer M, Gordon N, Knudsen K, Simpkins F, Gilad O, Brown EJ. Abstract A16: Potent and selective ATR inhibitors for the treatment of homologous-recombination deficient and PARPi-resistant cancers Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-A16 |
0.445 |
|
| 2017 |
Schiewer MJ, Mandigo AC, Gordon N, Han S, Zhao S, Evans J, Parsons T, Birbe R, McCue P, Visakorpi T, Raj G, Rubin M, Bono Jd, Lallas C, Trabulsi E, ... ... Knudsen KE, et al. Abstract A08: PARP1-mediated E2F1 regulation of DNA repair capacity Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-A08 |
0.445 |
|
| 2017 |
Knudsen KE. Abstract SY29-01: Targeting DNA repair factor dysfunction in advanced prostate cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Sy29-01 |
0.567 |
|
| 2017 |
Dylgjeri E, Goodwin JF, McNair CM, Shafi AA, Kothari V, Feng F, Rathkop D, Knudsen K. Abstract LB-264: Preclinical evaluation of DNA-PK as a therapeutic target in prostate cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-264 |
0.486 |
|
| 2017 |
Brand LJ, Zaslavsky AB, Palapattu GS, Knudsen KE. Abstract LB-185: A PSMA-directed natural killer cell approach for prostate cancer immunotherapy Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-185 |
0.577 |
|
| 2017 |
Shafi AA, Schiewer MJ, Leeuw Rd, McCue PA, Gomella LG, Lallas CD, Trabulsi EJ, Hickey T, Shah N, Cukierman E, Butler LM, Tilley W, Raj G, Knudsen KE. Abstract LB-109: PDeX (Patient Derived eXplant) models to determine the basis for response to targeted agents in prostate cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-109 |
0.541 |
|
| 2017 |
McNair C, Xu K, Mandigo A, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Visakorpi T, Li F, Bono JD, Demichelis F, Rubin M, Brown M, Knudsen KE. Abstract LB-085: RB loss-induced genome wide E2F1 reprogramming drive advanced prostate cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-085 |
0.5 |
|
| 2017 |
McCann JJ, Dean JL, Leeuw RD, Schiewer MJ, McNair CM, Knudsen KE. Abstract LB-030: Specific missense mutations inTP53elicit contrasting biochemical and biological outcomes affecting prostate cancer progression Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-030 |
0.494 |
|
| 2017 |
Leeuw Rd, Schiewer MJ, McNair C, Augello MA, Yoshida A, Hazard ES, Courtney S, Hardiman GT, Drake J, Feng FY, Tomlins S, Hussain MH, Diehl JA, Kelly WK, Knudsen KE. Abstract 5874: Cdk4/6 kinase inhibitor resistance in prostate cancer Cancer Research. 77: 5874-5874. DOI: 10.1158/1538-7445.Am2017-5874 |
0.486 |
|
| 2016 |
Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment S, Cotzia P, Dean JL, Snook AE, McNair C, Price MA, Hernandez JR, ... ... Knudsen KE, et al. RB loss promotes prostate cancer metastasis. Cancer Research. PMID 27923835 DOI: 10.1158/0008-5472.Can-16-1589 |
0.563 |
|
| 2016 |
Knudsen KE. There and Back Again: The Middle Earth of DNA Repair. Molecular Cancer Research : McR. 14: 895-897. PMID 27742842 DOI: 10.1158/1541-7786.Mcr-16-0298 |
0.349 |
|
| 2016 |
Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, et al. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports. 9: 51-54. PMID 27713863 DOI: 10.1016/J.Eucr.2016.08.010 |
0.378 |
|
| 2016 |
McNair C, Urbanucci A, Comstock CE, Augello MA, Goodwin JF, Launchbury R, Zhao SG, Schiewer MJ, Ertel A, Karnes J, Davicioni E, Wang L, Wang Q, Mills IG, Feng FY, ... ... Knudsen KE, et al. Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene. PMID 27669432 DOI: 10.1038/Onc.2016.334 |
0.794 |
|
| 2016 |
Schiewer MJ, Knudsen KE. Linking DNA Damage and Hormone Signaling Pathways in Cancer. Trends in Endocrinology and Metabolism: Tem. 27: 216-25. PMID 26944914 DOI: 10.1016/J.Tem.2016.02.004 |
0.435 |
|
| 2016 |
Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, ... ... Knudsen KE, et al. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. Jama Oncology. 1-10. PMID 26746117 DOI: 10.1001/Jamaoncol.2015.4955 |
0.454 |
|
| 2016 |
Schiewer MJ, Knudsen KE. PARPi in PCa results in decreased availability of DNA repair factors. Journal of Clinical Oncology. 34: 301-301. DOI: 10.1200/Jco.2016.34.2_Suppl.301 |
0.47 |
|
| 2016 |
Schiewer MJ, Gitman RS, Trabulsi EJ, DeAngelis T, Kelly WK, Gomella LG, Knudsen KE, Dicker A, Simone NL. Effect of caloric restriction on the efficacy of radiation in both hormone-sensitive and hormone-resistant prostate cancers. Journal of Clinical Oncology. 34: 16-16. DOI: 10.1200/Jco.2016.34.2_Suppl.16 |
0.478 |
|
| 2016 |
Slovin SF, Knudsen KE, Carbone E, Showunmi A, Hullings M, Morris MJ, Autio KA, Kampel LJ, Molina AM, Chen Y, Arauz G, Curley T, Tse K, Halabi S, Scher HI, et al. Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps5093 |
0.506 |
|
| 2016 |
Shafi A, Schiewer M, Leeuw Rd, McCue P, Birbe R, Gomella L, Lallas C, Trabulsi E, Raj G, Knudsen K. Abstract A12: Developing PDeX (Patient Derived Explant) to determine the basis for response to AR-directed therapeutics Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-A12 |
0.499 |
|
| 2016 |
Hussain M, Palmbos PL, Tomlins SA, Daignault-Newton S, Agarwal N, Twardowski P, Morgans AK, Antonarakis ES, Knudsen KE, Feng FY. Abstract IA06: Co-Targeting cell cycle and androgen signaling to personalize therapy for hormone dependent prostate cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Cellcycle16-Ia06 |
0.59 |
|
| 2016 |
Mandigo AC, McNair C, Schiewer MJ, Xu K, Li F, Myles B, Knudsen KE. Abstract B11: Re-wired E2F function in response to RB loss as a potential driver of castration-resistant prostate cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Cellcycle16-B11 |
0.623 |
|
| 2016 |
Thangavel C, Boopathi E, Liu Y, Haber A, Perepelyuk M, Addya S, Shoyele S, Dicker AP, Knudsen KE, Den RB. Abstract B08: Retinoblastoma protein orchestrates cellular apoptosis in non-small cell lung cancer in response to CDK4/6 inhibition: novel targets and key mechanisms Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Cellcycle16-B08 |
0.41 |
|
| 2016 |
Chand SN, Zarei M, Kamath AR, Schiewer MJ, Romeo C, Cozzitorto JA, Meisner-Kober N, Londin E, Rigoutsos I, Knudsen K, Pascal JM, Yeo CJ, Winter JM, Brody JR. Abstract 1995: HuR dependent inhibition of PARG enhances PARP inhibitor therapy for DNA repair proficient and deficient pancreatic cancer cells Cancer Research. 76: 1995-1995. DOI: 10.1158/1538-7445.Am2016-1995 |
0.361 |
|
| 2016 |
Simone B, Dan T, Palagani A, DeAngelis T, Schiewer M, Knudsen K, Dicker A, Simone N. Caloric Restriction Augments the Molecular Effects of Radiation in Both Hormone-Sensitive and Hormone-Insensitive Prostate Cancers by Decreasing Inflammation International Journal of Radiation Oncology*Biology*Physics. 96: S76. DOI: 10.1016/J.Ijrobp.2016.06.193 |
0.493 |
|
| 2015 |
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, ... ... Knudsen KE, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. The New England Journal of Medicine. 373: 1697-1708. PMID 26510020 DOI: 10.1056/Nejmoa1506859 |
0.533 |
|
| 2015 |
Schrecengost RS, Keller SN, Schiewer MJ, Knudsen KE, Smith CD. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Molecular Cancer Research : McR. PMID 26271487 DOI: 10.1158/1541-7786.Mcr-14-0626 |
0.585 |
|
| 2015 |
Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, ... ... Knudsen KE, et al. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell. 28: 97-113. PMID 26175416 DOI: 10.1016/J.Ccell.2015.06.004 |
0.381 |
|
| 2015 |
Feng FY, de Bono JS, Rubin MA, Knudsen KE. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Molecular Cell. 58: 925-34. PMID 26091341 DOI: 10.1016/J.Molcel.2015.04.016 |
0.353 |
|
| 2015 |
Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, ... ... Knudsen KE, et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia (New York, N.Y.). 17: 385-99. PMID 25925381 DOI: 10.1016/J.Neo.2015.03.004 |
0.407 |
|
| 2015 |
Augello MA, Berman-Booty LD, Carr R, Yoshida A, Dean JL, Schiewer MJ, Feng FY, Tomlins SA, Gao E, Koch WJ, Benovic JL, Diehl JA, Knudsen KE. Consequence of the tumor-associated conversion to cyclin D1b. Embo Molecular Medicine. 7: 628-47. PMID 25787974 DOI: 10.15252/Emmm.201404242 |
0.433 |
|
| 2015 |
Grasso CS, Cani AK, Hovelson DH, Quist MJ, Douville NJ, Yadati V, Amin AM, Nelson PS, Betz BL, Liu CJ, Knudsen KE, Cooney KA, Feng FY, McDaniel AS, Tomlins SA. Integrative molecular profiling of routine clinical prostate cancer specimens. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1110-8. PMID 25735316 DOI: 10.1093/Annonc/Mdv134 |
0.512 |
|
| 2015 |
Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America. 112: E1106-15. PMID 25713380 DOI: 10.1073/Pnas.1420955112 |
0.652 |
|
| 2015 |
de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, Kelly WK, Trabulsi EJ, Lallas CD, Gomella LG, Knudsen KE. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 795-807. PMID 25691773 DOI: 10.1158/1078-0432.Ccr-14-1358 |
0.535 |
|
| 2015 |
Koryakina Y, Knudsen KE, Gioeli D. Cell-cycle-dependent regulation of androgen receptor function. Endocrine-Related Cancer. 22: 249-64. PMID 25691442 DOI: 10.1530/Erc-14-0549 |
0.481 |
|
| 2015 |
Berman-Booty LD, Knudsen KE. Models of neuroendocrine prostate cancer. Endocrine-Related Cancer. 22: R33-49. PMID 25349195 DOI: 10.1530/Erc-14-0393 |
0.565 |
|
| 2015 |
Palmbos PL, Feng FY, Tomlins SA, Kelly WK, Morgans AK, Taplin M, Agarwal N, Antonarakis ES, Twardowski P, Jacobson J, Davenport MS, Daignault S, Knudsen KE, Hussain M. A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology. 33: TPS5074-TPS5074. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps5074 |
0.51 |
|
| 2015 |
Heine E, Merry DE, Dehm S, Knudsen KE, Montie HL. Abstract 87: Targeting androgen receptor acetylation as a treatment for castrate-resistant prostate cancer Cancer Research. 75: 87-87. DOI: 10.1158/1538-7445.Am2015-87 |
0.59 |
|
| 2015 |
Schiewer MJ, Han S, Evans J, Augello MA, Berman-Booty L, Parsons T, Birbe R, Dicker AP, Kelly WK, Gomella LG, Feng F, Knudsen KE. Abstract 5054: Discerning the PARP-dependent AR cistrome/transcriptome in prostate cancer Endocrinology. 75: 5054-5054. DOI: 10.1158/1538-7445.Am2015-5054 |
0.569 |
|
| 2015 |
Kothari V, Goodwin JF, Zhao S, Davicioni E, Karnes JR, Den RB, Mehra R, Knudsen KE, Feng FY. Abstract 2853: Investigating DNAPK as a biomarker and a novel therapeutic target in aggressive prostate cancer Cancer Research. 75: 2853-2853. DOI: 10.1158/1538-7445.Am2015-2853 |
0.528 |
|
| 2015 |
Jones J, Dean JL, Schrecengost RS, Knudsen K. Abstract 1862: Discerning the role of USP22 in prostate cancer development and progression Cancer Research. 75: 1862-1862. DOI: 10.1158/1538-7445.Am2015-1862 |
0.607 |
|
| 2015 |
Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Magee MS, Den RB, Zhu Z, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, ... ... Knudsen KE, et al. Abstract 1860: DNA-PK-mediated transcriptional regulation drives tumor progression and metastasis Endocrinology. 75: 1860-1860. DOI: 10.1158/1538-7445.Am2015-1860 |
0.364 |
|
| 2015 |
Dylgjeri E, Goodwin J, Knudsen K. Abstract 1859: Discerning the molecular basis of DNA-PK pro-tumorigenic functions and translational capacity as a therapeutic target in prostate cancer Cancer Research. 75: 1859-1859. DOI: 10.1158/1538-7445.Am2015-1859 |
0.473 |
|
| 2015 |
McNair C, Goodwin J, Augello M, Urbanucci A, Schiewer M, Comstock C, Ertel A, Wang L, Wang Q, Mills I, Li W, Carroll J, Knudsen K. Abstract 1844: Genome wide analysis of AR-cell cycle interplay reveals novel functions in cancer Cancer Research. 75: 1844-1844. DOI: 10.1158/1538-7445.Am2015-1844 |
0.772 |
|
| 2015 |
Leeuw Rd, Berman-Booty L, Schiewer M, Ciment S, Den R, Dicker A, Kelly W, Trabulsi E, Lallas C, Gomella L, Knudsen K. Abstract 1843: Novel actions of next-generation taxanes benefit advanced stages of prostate cancer Cancer Research. 75: 1843-1843. DOI: 10.1158/1538-7445.Am2015-1843 |
0.582 |
|
| 2015 |
Han SY, Dan TD, Angelis TD, Han JY, Sarich M, Carroll P, Knudsen K, Dicker A, Simone NL. Abstract 1790: Caloric restriction can increase the efficacy of radiation in both hormone-sensitive and hormone-resistant prostate cancers by downregulating the IGF-1R pathway Cancer Research. 75: 1790-1790. DOI: 10.1158/1538-7445.Am2015-1790 |
0.53 |
|
| 2015 |
Dean JL, Jones JK, Goodwin JF, Knudsen KE. Abstract 1217: Determining the impact of CRPC-specific p53 mutation on therapeutic response and prostate tumor progression Cancer Research. 75: 1217-1217. DOI: 10.1158/1538-7445.Am2015-1217 |
0.541 |
|
| 2015 |
Schrecengost RS, Keller S, Schiewer M, Knudsen K, Smith C. Abstract C94: Dual downregulation of Myc and AR with a sphingosine kinase-2 inhibitor prevents prostate cancer progression Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C94 |
0.566 |
|
| 2015 |
Evans JR, Zhao SG, Tomlins SA, Knudsen KE, Bono JSd, Rubin MA, Klein EA, Den RB, Dicker AP, Karnes JR, Davicioni E, Feng FY. Patient-Level DNA Damage and Repair Pathway Profiles Are Prognostic After Prostatectomy for High-Risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.321 |
0.46 |
|
| 2014 |
Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, Lawrence TS, Chinnaiyan AM, Feng FY. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia (New York, N.Y.). 16: 900-8. PMID 25425964 DOI: 10.1016/J.Neo.2014.09.001 |
0.525 |
|
| 2014 |
Goodwin JF, Knudsen KE. Beyond DNA repair: DNA-PK function in cancer. Cancer Discovery. 4: 1126-39. PMID 25168287 DOI: 10.1158/2159-8290.Cd-14-0358 |
0.303 |
|
| 2014 |
Thangavel C, Boopathi E, Ciment S, Liu Y, O' Neill R, Sharma A, McMahon SB, Mellert H, Addya S, Ertel A, Birbe R, Fortina P, Dicker AP, Knudsen KE, Den RB. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5468-82. PMID 25165096 DOI: 10.1158/1078-0432.Ccr-14-0326 |
0.482 |
|
| 2014 |
Knudsen KE. Hormone whodunit: clues for solving the case of intratumor androgen production. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5343-5. PMID 25135482 DOI: 10.1158/1078-0432.Ccr-14-1188 |
0.478 |
|
| 2014 |
Jimbo M, Knudsen KE, Brody JR. Fusing transcriptomics to progressive prostate cancer. The American Journal of Pathology. 184: 2608-10. PMID 25128905 DOI: 10.1016/J.Ajpath.2014.08.001 |
0.526 |
|
| 2014 |
Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 89: 1038-46. PMID 25035207 DOI: 10.1016/J.Ijrobp.2014.04.052 |
0.362 |
|
| 2014 |
Schiewer MJ, Knudsen KE. Transcriptional roles of PARP1 in cancer. Molecular Cancer Research : McR. 12: 1069-80. PMID 24916104 DOI: 10.1158/1541-7786.Mcr-13-0672 |
0.397 |
|
| 2014 |
Den RB, Doyle LA, Knudsen KE. Practical guide to the use of radium 223 dichloride. The Canadian Journal of Urology. 21: 70-6. PMID 24775727 |
0.368 |
|
| 2014 |
Dressing GE, Knutson TP, Schiewer MJ, Daniel AR, Hagan CR, Diep CH, Knudsen KE, Lange CA. Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 28: 442-57. PMID 24606123 DOI: 10.1210/Me.2013-1196 |
0.465 |
|
| 2014 |
Schiewer MJ, Knudsen KE. AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy. Embo Molecular Medicine. 6: 439-41. PMID 24562461 DOI: 10.1002/Emmm.201303737 |
0.558 |
|
| 2014 |
Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, ... Knudsen KE, et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Research. 74: 1651-60. PMID 24473064 DOI: 10.1158/0008-5472.Can-13-3159 |
0.494 |
|
| 2014 |
Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. Cancer Metastasis Reviews. 33: 399-411. PMID 24425228 DOI: 10.1007/S10555-013-9471-3 |
0.582 |
|
| 2014 |
Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC, Draganova-Tacheva RA, Visakorpi T, DeMarzo AM, McMahon SB, Knudsen KE. USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Research. 74: 272-86. PMID 24197134 DOI: 10.1158/0008-5472.Can-13-1954 |
0.505 |
|
| 2014 |
Steffen JD, Tholey RM, Langelier MF, Planck JL, Schiewer MJ, Lal S, Bildzukewicz NA, Yeo CJ, Knudsen KE, Brody JR, Pascal JM. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Research. 74: 31-7. PMID 24189460 DOI: 10.1158/0008-5472.Can-13-1701 |
0.38 |
|
| 2014 |
de Leeuw R, Comstock Cd, Pollutri Dd, Schiewer MJ, Ciment SJ, Mankame Td, Ostrander W, Den RB, Kelly WK, Gomella LG, Dicker A, Hussain M, Knudsen KE. Leveraging RB status to define therapy for castrate-resistant prostate cancer. Journal of Clinical Oncology. 32: 96-96. DOI: 10.1200/Jco.2014.32.4_Suppl.96 |
0.579 |
|
| 2014 |
Schiewer MJ, Steffen J, Tholey R, Brody JR, Pascal J, Lin J, Den R, Feng FY, Gomella LG, Dicker A, Kelly WK, Knudsen KE. Leveraging the DNA damage and transcriptional-regulatory roles of PARP-1 as a means to improve prostate cancer therapy. Journal of Clinical Oncology. 32: 179-179. DOI: 10.1200/Jco.2014.32.4_Suppl.179 |
0.575 |
|
| 2014 |
Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Birbe RC, McCue P, Ghadessi M, Knudsen KE, Dicker A. Validation of a genomic classifier for predicting biochemical failure following postoperative radiation therapy in high-risk prostate cancer. Journal of Clinical Oncology. 32: 10-10. DOI: 10.1200/Jco.2014.32.4_Suppl.10 |
0.361 |
|
| 2014 |
Trabulsi E, Karnes J, Feng F, Showalter T, Mishra M, Lallas C, Gomella L, Birbe R, McCue P, Ghadessi M, Buerki C, Davicioni E, Knudsen K, Dicker A, Den R. MP79-01 VALIDATION OF A GENOMIC CLASSIFIER FOR PREDICTING CLINICAL PROGRESSION FOLLOWING POST-OPERATIVE RADIATION THERAPY IN HIGH-RISK PROSTATE CANCER Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2504 |
0.435 |
|
| 2014 |
Den R, Karnes R, Feng F, Showalter T, Mishra M, Trabulsi E, Lallas C, Gomella L, Birbe R, McCue P, Yousefi K, Ghadessi M, Davicioni E, Kelly W, Knudsen K, et al. Validation of a Genomic Classifier for Predicting Metastasis Following Postoperative Radiation Therapy in High-Risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S157. DOI: 10.1016/J.Ijrobp.2014.05.641 |
0.375 |
|
| 2014 |
Schrecengost RS, Augello MA, Knudsen KE. Androgen receptor regulation of prostate cancer progression and metastasis Signaling Pathways and Molecular Mediators in Metastasis. 277-309. DOI: 10.1007/978-94-007-2558-4_12 |
0.513 |
|
| 2013 |
Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng FY. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia (New York, N.Y.). 15: 1207-17. PMID 24204199 DOI: 10.1593/Neo.131604 |
0.51 |
|
| 2013 |
Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, Ma T, Den RB, Dicker AP, Feng FY, Knudsen KE. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discovery. 3: 1254-71. PMID 24027197 DOI: 10.1158/2159-8290.Cd-13-0108 |
0.365 |
|
| 2013 |
Comstock CE, Knudsen KE. IGF2 revs the steroidogenesis engine. Endocrine-Related Cancer. 20: C19-21. PMID 23818573 DOI: 10.1530/Erc-13-0243 |
0.753 |
|
| 2013 |
Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Seminars in Oncology. 40: 244-58. PMID 23806491 DOI: 10.1053/J.Seminoncol.2013.04.001 |
0.565 |
|
| 2013 |
Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo culture of human prostate tissue and drug development. Nature Reviews. Urology. 10: 483-7. PMID 23752995 DOI: 10.1038/Nrurol.2013.126 |
0.48 |
|
| 2013 |
Comstock CE, Augello MA, Goodwin JF, de Leeuw R, Schiewer MJ, Ostrander WF, Burkhart RA, McClendon AK, McCue PA, Trabulsi EJ, Lallas CD, Gomella LG, Centenera MM, Brody JR, Butler LM, ... ... Knudsen KE, et al. Targeting cell cycle and hormone receptor pathways in cancer. Oncogene. 32: 5481-91. PMID 23708653 DOI: 10.1038/Onc.2013.83 |
0.74 |
|
| 2013 |
Balasubramaniam S, Comstock CE, Ertel A, Jeong KW, Stallcup MR, Addya S, McCue PA, Ostrander WF, Augello MA, Knudsen KE. Aberrant BAF57 signaling facilitates prometastatic phenotypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2657-67. PMID 23493350 DOI: 10.1158/1078-0432.Ccr-12-3049 |
0.799 |
|
| 2013 |
Dean JL, Knudsen KE. The role of tumor suppressor dysregulation in prostate cancer progression. Current Drug Targets. 14: 460-71. PMID 23410128 DOI: 10.2174/1389450111314040007 |
0.627 |
|
| 2013 |
Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, ... ... Knudsen KE, et al. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. The Journal of Clinical Investigation. 123: 493-508. PMID 23257359 DOI: 10.1172/Jci64750 |
0.815 |
|
| 2013 |
Schrecengost R, Dean J, Stanek T, Birbe R, Hicks J, Visakorpi T, DeMarzo A, McMahon S, Knudsen K. Abstract 3576: USP22 modulates AR activity to critically regulate prostate cancer progression. Cancer Research. 73: 3576-3576. DOI: 10.1158/1538-7445.Am2013-3576 |
0.621 |
|
| 2013 |
Goodwin JF, Schiewer MJ, Feng FY, Knudsen KE. Abstract 1071: Impact of AR activation status on the DNA damage response. Cancer Research. 73: 1071-1071. DOI: 10.1158/1538-7445.Am2013-1071 |
0.492 |
|
| 2012 |
Den RB, Ciment S, Sharma A, Mellert H, McMahon S, Dicker A, Knudsen KE. Differential response of prostate cancer cells to ionizing radiation: The RB status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 106. PMID 28143057 DOI: 10.1200/jco.2012.30.5_suppl.106 |
0.459 |
|
| 2012 |
Den RB, Ciment S, Sharma A, Mellert H, McMahon S, Dicker A, Knudsen KE. Differential response of prostate cancer cells to ionizing radiation: The RB status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 106. PMID 27968000 DOI: 10.1200/Jco.2012.30.5_Suppl.106 |
0.548 |
|
| 2012 |
Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, ... ... Knudsen KE, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery. 2: 1134-49. PMID 22993403 DOI: 10.1158/2159-8290.Cd-12-0120 |
0.612 |
|
| 2012 |
Knudsen KE. Cyclin D1 goes metabolic: dual functions of cyclin D1 in regulating lipogenesis. Cell Cycle (Georgetown, Tex.). 11: 3533-4. PMID 22951541 DOI: 10.4161/Cc.22039 |
0.441 |
|
| 2012 |
Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Tilley WD, Butler LM. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3562-70. PMID 22573351 DOI: 10.1158/1078-0432.Ccr-12-0782 |
0.533 |
|
| 2012 |
Shah S, Prasad S, Knudsen KE. Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. Cancer Research. 72: 1248-59. PMID 22258452 DOI: 10.1158/0008-5472.Can-11-0943 |
0.554 |
|
| 2012 |
Schiewer MJ, Den R, Hoang DT, Augello MA, Lawrence YR, Dicker AP, Knudsen KE. mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocrine-Related Cancer. 19: 1-12. PMID 21903859 DOI: 10.1530/Erc-11-0072 |
0.486 |
|
| 2012 |
Schiewer MJ, Augello MA, Knudsen KE. The AR dependent cell cycle: mechanisms and cancer relevance. Molecular and Cellular Endocrinology. 352: 34-45. PMID 21782001 DOI: 10.1016/J.Mce.2011.06.033 |
0.552 |
|
| 2012 |
Schiewer MJ, Dicker AP, Brody JR, Pascal JM, Knudsen KE, Goodwin JF, Brenner JC, Augello MA, Liu F, Planck JL, Schrecengost RS, Feng FY, Chinnaiyan AM. Abstract IA9: Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance Cancer Research. 72: IA9-IA9. DOI: 10.1158/1538-7445.PRCA2012-IA9 |
0.433 |
|
| 2012 |
Schiewer MJ, Dicker AP, Brody JR, Pascal JM, Butler LM, Tilley WD, Feng FY, Knudsen KE, Goodwin JF, Brenner JC, Augello MA, Liu F, Planck JL, Schrecengost RS, Chinnaiyan AM, et al. Abstract C8: Targeting the DNA-damage repair and transcriptional regulatory functions of PARP1 therapeutically in prostate cancer Cancer Research. 72: C8-C8. DOI: 10.1158/1538-7445.PRCA2012-C8 |
0.394 |
|
| 2012 |
Den RB, Ciment S, Sharma A, Mellert H, McMahon S, Dicker AP, Knudsen KE. Abstract C15: RB status alters the response of prostate cancer to ionizing radiation Cancer Research. 72: C15-C15. DOI: 10.1158/1538-7445.Prca2012-C15 |
0.528 |
|
| 2012 |
Augello MA, Burd C, Bribe R, Frigo D, Karch J, McDonnell D, Visakorpi T, Knudsen KE. Abstract A50: Cyclin D1 isoforms selectively manipulate AR signaling to promote metastatic phenotypes in early and castration-resistant prostate cancer. Cancer Research. 72: A50-A50. DOI: 10.1158/1538-7445.Prca2012-A50 |
0.833 |
|
| 2011 |
Den RB, Ciment S, Sharma A, Mellert H, Mc-Mahon S, Dicker A, Knudsen KE. Relationship between the loss of the retinoblastoma tumor suppressor and radiosensitivity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 34. PMID 27968373 DOI: 10.1200/Jco.2011.29.7_Suppl.34 |
0.546 |
|
| 2011 |
Knudsen KE, Kelly WK. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Review of Endocrinology & Metabolism. 6: 483-493. PMID 22389648 DOI: 10.1586/Eem.11.33 |
0.588 |
|
| 2011 |
Mishra MV, Champ CE, Den RB, Scher ED, Shen X, Trabulsi EJ, Lallas CD, Knudsen KE, Dicker AP, Showalter TN. Postprostatectomy radiation therapy: an evidence-based review. Future Oncology (London, England). 7: 1429-40. PMID 22112318 DOI: 10.2217/Fon.11.120 |
0.362 |
|
| 2011 |
Augello MA, Hickey TE, Knudsen KE. FOXA1: Master of steroid receptor function in cancer Embo Journal. 30: 3885-3894. PMID 21934649 DOI: 10.1038/Emboj.2011.340 |
0.468 |
|
| 2011 |
Gerhart J, Scheinfeld VL, Milito T, Pfautz J, Neely C, Fisher-Vance D, Sutter K, Crawford M, Knudsen K, George-Weinstein M. Myo/Nog cell regulation of bone morphogenetic protein signaling in the blastocyst is essential for normal morphogenesis and striated muscle lineage specification. Developmental Biology. 359: 12-25. PMID 21884693 DOI: 10.1016/J.Ydbio.2011.08.007 |
0.303 |
|
| 2011 |
Aparicio A, Den RB, Knudsen KE. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nature Reviews. Urology. 8: 562-8. PMID 21811228 DOI: 10.1038/Nrurol.2011.107 |
0.592 |
|
| 2011 |
Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (Georgetown, Tex.). 10: 2497-503. PMID 21775818 DOI: 10.4161/Cc.10.15.16776 |
0.358 |
|
| 2011 |
Bryant KG, Camacho J, Jasmin JF, Wang C, Addya S, Casimiro MC, Fortina P, Balasubramaniam S, Knudsen KE, Schwarting R, Lisanti MP, Mercier I. Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. The International Journal of Biochemistry & Cell Biology. 43: 1318-29. PMID 21601007 DOI: 10.1016/J.Biocel.2011.04.019 |
0.59 |
|
| 2011 |
Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen ES. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocrine-Related Cancer. 18: 333-45. PMID 21367843 DOI: 10.1530/Erc-10-0262 |
0.431 |
|
| 2011 |
Knudsen KE. A tale of three PKCs: epsilon emerges as a driver of pre-neoplastic phenotypes. Cell Cycle (Georgetown, Tex.). 10: 379. PMID 21270526 DOI: 10.4161/Cc.10.3.14740 |
0.416 |
|
| 2011 |
Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A, Knudsen ES, Jessen WJ, Aronow BJ, Knudsen KE. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. The Journal of Biological Chemistry. 286: 8117-27. PMID 21212260 DOI: 10.1074/Jbc.M110.170720 |
0.835 |
|
| 2011 |
McClendon AK, Ertel A, Dean J, Thangavel C, Knudsen KE, Witkiewicz AK, Knudsen ES. Abstract 2982: Impact of the RB-pathway in breast cancer heterogeneity and therapeutic response Cancer Research. 71: 2982-2982. DOI: 10.1158/1538-7445.Am2011-2982 |
0.418 |
|
| 2010 |
Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK, Gomella L, Knudsen ES, Nelson PS, Knudsen KE. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. The Journal of Clinical Investigation. 120: 4478-92. PMID 21099110 DOI: 10.1172/Jci44239 |
0.804 |
|
| 2010 |
Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (Georgetown, Tex.). 9: 4153-63. PMID 20948315 DOI: 10.4161/Cc.9.20.13454 |
0.366 |
|
| 2010 |
Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C, Zhang J, Parysek LM, Knudsen KE. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Research. 70: 3975-84. PMID 20460515 DOI: 10.1158/0008-5472.Can-09-3468 |
0.775 |
|
| 2010 |
Flores O, Wang Z, Knudsen KE, Burnstein KL. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology. 151: 896-908. PMID 20147522 DOI: 10.1210/En.2009-1116 |
0.494 |
|
| 2010 |
Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism: Tem. 21: 315-24. PMID 20138542 DOI: 10.1016/J.Tem.2010.01.002 |
0.614 |
|
| 2010 |
Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, Comstock C, Hyslop T, Knudsen KE, Sette C. Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Research. 70: 229-39. PMID 20028857 DOI: 10.1158/0008-5472.Can-09-2788 |
0.79 |
|
| 2010 |
Augello M, Burd C, Karch J, Knudsen K. Abstract 3878: Perturbations in the AR-cyclin D1 axis controls lethal tumor phenotypes in prostate cancer Cancer Research. 70: 3878-3878. DOI: 10.1158/1538-7445.Am10-3878 |
0.848 |
|
| 2010 |
Schiewer MJ, Goodwin J, Knudsen KE. Abstract 1706: Impact of PARP1 on AR signaling and therapeutic response in prostate cancer Cancer Research. 70: 1706-1706. DOI: 10.1158/1538-7445.Am10-1706 |
0.581 |
|
| 2010 |
Gan L, Liu P, Lu H, Chen S, Yang J, McCarthy JB, Knudsen KE, Huang H. Erratum: Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis Cell Death & Differentiation. 17: 900-900. DOI: 10.1038/Cdd.2010.15 |
0.369 |
|
| 2009 |
Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Research. 69: 8223-30. PMID 19843852 DOI: 10.1158/0008-5472.Can-09-2166 |
0.401 |
|
| 2009 |
Miao J, Fang S, Lee J, Comstock C, Knudsen KE, Kemper JK. Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Molecular and Cellular Biology. 29: 6170-81. PMID 19805516 DOI: 10.1128/Mcb.00825-09 |
0.703 |
|
| 2009 |
Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, ... ... Knudsen KE, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5338-49. PMID 19706803 DOI: 10.1158/1078-0432.Ccr-08-2865 |
0.848 |
|
| 2009 |
Knudsen KE, Scher HI. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer Clinical Cancer Research. 15: 4792-4798. PMID 19638458 DOI: 10.1158/1078-0432.Ccr-08-2660 |
0.592 |
|
| 2009 |
Gan L, Liu P, Lu H, Chen S, Yang J, McCarthy JB, Knudsen KE, Huang H. Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis. Cell Death & Differentiation. 16: 1408-1417. PMID 19575018 DOI: 10.1038/Cdd.2009.86 |
0.467 |
|
| 2009 |
Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, ... Knudsen KE, et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 28: 1812-20. PMID 19287456 DOI: 10.1038/Onc.2009.13 |
0.723 |
|
| 2009 |
Schiewer MJ, Morey LM, Burd CJ, Liu Y, Merry DE, Ho SM, Knudsen KE. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer Oncogene. 28: 1016-1027. PMID 19079343 DOI: 10.1038/Onc.2008.446 |
0.831 |
|
| 2008 |
Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nature Reviews. Cancer. 8: 714-24. PMID 19143056 DOI: 10.1038/Nrc2401 |
0.334 |
|
| 2008 |
Shen H, Powers N, Saini N, Comstock CE, Sharma A, Weaver K, Revelo MP, Gerald W, Williams E, Jessen WJ, Aronow BJ, Rosson G, Weissman B, Muchardt C, Yaniv M, ... Knudsen KE, et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Research. 68: 10154-62. PMID 19074882 DOI: 10.1158/0008-5472.Can-08-1794 |
0.819 |
|
| 2008 |
Shah S, Hess-Wilson JK, Webb S, Daly H, Godoy-Tundidor S, Kim J, Boldison J, Daaka Y, Knudsen KE. 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways. Molecular Cancer Research : McR. 6: 1507-20. PMID 18819937 DOI: 10.1158/1541-7786.Mcr-07-2166 |
0.579 |
|
| 2008 |
Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Research. 68: 5628-38. PMID 18632615 DOI: 10.1158/0008-5472.Can-07-3170 |
0.769 |
|
| 2008 |
Link KA, Balasubramaniam S, Sharma A, Comstock CE, Godoy-Tundidor S, Powers N, Cao KH, Haelens A, Claessens F, Revelo MP, Knudsen KE. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Research. 68: 4551-8. PMID 18559499 DOI: 10.1158/0008-5472.Can-07-6392 |
0.823 |
|
| 2008 |
Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nuclear Receptor Signaling. 6: e001. PMID 18301781 DOI: 10.1621/Nrs.06001 |
0.639 |
|
| 2008 |
Olshavsky NA, Groh EM, Comstock CE, Morey LM, Wang Y, Revelo MP, Burd C, Meller J, Knudsen KE. Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene. 27: 3111-21. PMID 18084330 DOI: 10.1038/Sj.Onc.1210981 |
0.846 |
|
| 2007 |
Hess-Wilson JK, Webb SL, Daly HK, Leung YK, Boldison J, Comstock CE, Sartor MA, Ho SM, Knudsen KE. Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environmental Health Perspectives. 115: 1646-53. PMID 18007998 DOI: 10.1289/Ehp.10283 |
0.83 |
|
| 2007 |
vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain DA, Eriksen M, Farabollini F, Guillette LJ, Hauser R, Heindel JJ, Ho SM, Hunt PA, Iguchi T, Jobling S, Kanno J, ... ... Knudsen KE, et al. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reproductive Toxicology (Elmsford, N.Y.). 24: 131-8. PMID 17768031 DOI: 10.1016/J.Reprotox.2007.07.005 |
0.743 |
|
| 2007 |
Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, Barrera J, Knudsen KE. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Research. 67: 6192-203. PMID 17616676 DOI: 10.1158/0008-5472.Can-06-4424 |
0.821 |
|
| 2007 |
Comstock CE, Knudsen KE. The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. Cell Cycle (Georgetown, Tex.). 6: 1307-13. PMID 17568191 DOI: 10.4161/Cc.6.11.4353 |
0.805 |
|
| 2007 |
Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Research. 67: 3106-16. PMID 17409417 DOI: 10.1158/0008-5472.Can-06-3401 |
0.34 |
|
| 2007 |
Comstock CE, Revelo MP, Buncher CR, Knudsen KE. Impact of differential cyclin D1 expression and localisation in prostate cancer. British Journal of Cancer. 96: 970-9. PMID 17375037 DOI: 10.1038/Sj.Bjc.6603615 |
0.789 |
|
| 2007 |
Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. The Journal of Clinical Investigation. 117: 218-28. PMID 17160137 DOI: 10.1172/Jci28803 |
0.463 |
|
| 2006 |
Hess-Wilson JK, Daly HK, Zagorski WA, Montville CP, Knudsen KE. Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Research. 66: 11998-2008. PMID 17178899 DOI: 10.1158/0008-5472.Can-06-2249 |
0.613 |
|
| 2006 |
Wetherill YB, Hess-Wilson JK, Comstock CE, Shah SA, Buncher CR, Sallans L, Limbach PA, Schwemberger S, Babcock GF, Knudsen KE. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Molecular Cancer Therapeutics. 5: 3181-90. PMID 17172422 DOI: 10.1158/1535-7163.Mct-06-0272 |
0.843 |
|
| 2006 |
Burd CJ, Morey LM, Knudsen KE. Androgen receptor corepressors and prostate cancer. Endocrine-Related Cancer. 13: 979-94. PMID 17158750 DOI: 10.1677/Erc.1.01115 |
0.831 |
|
| 2006 |
Knudsen KE. The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Division. 1: 15. PMID 16863592 DOI: 10.1186/1747-1028-1-15 |
0.495 |
|
| 2006 |
Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Experimental Biology and Medicine (Maywood, N.J.). 231: 1271-81. PMID 16816134 DOI: 10.1177/153537020623100713 |
0.426 |
|
| 2006 |
Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 25: 1620-8. PMID 16550162 DOI: 10.1038/Sj.Onc.1209371 |
0.444 |
|
| 2006 |
Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation Proceedings of the National Academy of Sciences of the United States of America. 103: 2190-2195. PMID 16461912 DOI: 10.1073/Pnas.0506281103 |
0.842 |
|
| 2006 |
Hess-Wilson JK, Boldison J, Weaver KE, Knudsen KE. Xenoestrogen action in breast cancer: impact on ER-dependent transcription and mitogenesis. Breast Cancer Research and Treatment. 96: 279-92. PMID 16328721 DOI: 10.1007/S10549-005-9082-Y |
0.365 |
|
| 2005 |
Hess-Wilson JK, Knudsen KE. Endocrine disrupting compounds and prostate cancer. Cancer Letters. 241: 1-12. PMID 16298040 DOI: 10.1016/J.CANLET.2005.10.006 |
0.461 |
|
| 2005 |
Link KA, Burd CJ, Williams E, Marshall T, Rosson G, Henry E, Weissman B, Knudsen KE. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF Molecular and Cellular Biology. 25: 2200-2215. PMID 15743818 DOI: 10.1128/Mcb.25.6.2200-2215.2005 |
0.812 |
|
| 2005 |
Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Research. 65: 54-65. PMID 15665279 |
0.86 |
|
| 2005 |
Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, Diehl JA, Knudsen KE. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene. 24: 431-44. PMID 15558026 DOI: 10.1038/Sj.Onc.1208200 |
0.787 |
|
| 2005 |
Burd CJ, Petre CE, Moghadam H, Wilson EM, Knudsen KE. Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Molecular Endocrinology (Baltimore, Md.). 19: 607-20. PMID 15539430 DOI: 10.1210/Me.2004-0266 |
0.772 |
|
| 2004 |
Barnes-Ellerbe S, Knudsen KE, Puga A. 2,3,7,8-Tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. Molecular Pharmacology. 66: 502-11. PMID 15322241 DOI: 10.1124/Mol.104.000356 |
0.459 |
|
| 2003 |
Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE. Specificity of cyclin D1 for androgen receptor regulation. Cancer Research. 63: 4903-13. PMID 12941814 |
0.851 |
|
| 2003 |
Marshall TW, Link KA, Petre-Draviam CE, Knudsen KE. Differential requirement of SWI/SNF for androgen receptor activity. The Journal of Biological Chemistry. 278: 30605-13. PMID 12775722 DOI: 10.1074/Jbc.M304582200 |
0.546 |
|
| 2002 |
Wetherill YB, Petre CE, Monk KR, Puga A, Knudsen KE. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Molecular Cancer Therapeutics. 1: 515-24. PMID 12479269 |
0.856 |
|
| 2002 |
Strobeck MW, Reisman DN, Gunawardena RW, Betz BL, Angus SP, Knudsen KE, Kowalik TF, Weissman BE, Knudsen ES. Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. The Journal of Biological Chemistry. 277: 4782-9. PMID 11719516 DOI: 10.1074/Jbc.M109532200 |
0.377 |
|
| 2002 |
Petre CE, Wetherill YB, Danielsen M, Knudsen KE. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. The Journal of Biological Chemistry. 277: 2207-15. PMID 11714699 DOI: 10.1074/Jbc.M106399200 |
0.828 |
|
| 2001 |
Sever-Chroneos Z, Angus SP, Fribourg AF, Wan H, Todorov I, Knudsen KE, Knudsen ES. Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. Molecular and Cellular Biology. 21: 4032-45. PMID 11359910 DOI: 10.1128/Mcb.21.12.4032-4045.2001 |
0.386 |
|
| 2000 |
Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, Knudsen ES. RB-dependent S-phase response to DNA damage. Molecular and Cellular Biology. 20: 7751-63. PMID 11003670 DOI: 10.1128/Mcb.20.20.7751-7763.2000 |
0.328 |
|
| 2000 |
Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF, Weissman BE, Imbalzano AN, Knudsen ES. BRG-1 is required for RB-mediated cell cycle arrest. Proceedings of the National Academy of Sciences of the United States of America. 97: 7748-53. PMID 10884406 DOI: 10.1073/Pnas.97.14.7748 |
0.407 |
|
| 1999 |
Knudsen KE, Weber E, Arden KC, Cavenee WK, Feramisco JR, Knudsen ES. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene. 18: 5239-45. PMID 10498874 DOI: 10.1038/Sj.Onc.1202910 |
0.4 |
|
| 1999 |
Knudsen KE, Fribourg AF, Strobeck MW, Blanchard JM, Knudsen ES. Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest. The Journal of Biological Chemistry. 274: 27632-41. PMID 10488103 DOI: 10.1074/Jbc.274.39.27632 |
0.398 |
|
| Show low-probability matches. |